Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Biomarkers Webinars - Archived

Biomarkers generally refer to a signal/indicator that can be used to detect, for example, a cell type, a DNA sequence, or an aspect of organism health. As such, there are a wide range of topics covered here under the term biomarkers - from tools to profile a range of biomarkers, new ways to design biomarker-driven clinical trials to biomarker discovery and companion diagnostics. The biomarker webinars listed here are recordings of past events. Simply register, for free, for any webinar by clicking the download archive button on each webinar page. If biomarkers is to broad a term, don’t forget, you can search our webinar catalog using the search bar, or, if you’re looking for something more specific browse through our other topics.

  Synopsis Webinar Title Date

LifeScience - This webinar will examine the use of targeted clinical strategies are as a critical step towards improving success rates
Speakers: Dr. Richard K. Harrison, Chief Scientific Officer, Clarivate Analytics
Gavin Coney, Head of Clinical Products, Clarivate Analytics
Dr. Lee Lancashire, Principal Research Scientist, Clarivate Analytics
The Evolving Utilization of Specific Biomarker Roles Within Trial Design Jun 15, 2017

LifeSciences - Through quantitative analysis of IHC images, effective biomarkers can be predictors of disease prognosis and immune response of various immunotherapies.
Speaker: Belma Dogdas, PhD, Associate Principal Scientist, Merck, Inc.
Quantitative Immunohistochemistry for Development of Predictive Biomarkers in Oncology Clinical Trials May 10, 2017

LifeSciences - Learn how Covance and Global Specimen Solutions, Inc. can bring new insights to your research, using a fully-outsourced SaaS platform designed from the ground up to accommodate not just a few trials’ worth of data, but entire pipelines for rich answers in real time
Speaker: Amelia Warner, PharmD, RPh, CEO andFounder, Global Specimen Solutions, Inc.
Turning Biorepositories into Translational Science Treasure Troves: The Value of Uniquely Complete Data Sets May 4, 2017

LifeSciences - In this webinar, the speakers will discuss 3D Biology technology and the application of this novel approach in the study 75 lung cancer FFPE samples
Speakers: A. McGarry Houghton, MD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Joseph M. Beechem, PhD, Senior Vice President of Research and Development, NanoString Technologies
Enabling Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology Apr 27, 2017

LifeSciences -  Topics include scientific and clinical research insights on the principles of BOLD fMRI and its application as a clinical tool and drug development biomarker, design of an fMRI study, and an overview of the challenges and limitations of performing fMRI evaluation under an Investigational New Drug Application for drug development
Speakers: Maria Laura Blefari, PhD, Biomedical Engineer, WorldCare Clinical
Mykol Larvie, MD, PhD, Physician, Department of Radiology, Director of Molecular Neuroimaging, Massachusetts General Hospital
Functional Brain Imaging Using MRI: An Emerging Tool for Drug Development and Clinical Trials Oct 28, 2016

LifeSciences -  This webinar will discuss recent technological advances that have illuminated promising new approaches for immunogen design, vaccine delivery and vaccination
Speaker: Christos J. Petropoulos, PhD, Chief Scientific Officer, Monogram Biosciences, and Vice President, LabCorp
Leveraging Technological Advances to Overcome the Challenges of HIV Vaccine Development Oct 20, 2016

LifeSciences -  This webinar will address the spectrum of immunotherapy development considerations and their implications for drug developers
Speaker: Steven M. Anderson, PhD, Senior Vice President, Chief Scientific Officer, Covance
The Role of Biomarkers and Companion / Complementary Diagnostics in Immuno-Oncology Trials Oct 5, 2016

LifeSciences - The speaker will review the application was first evaluated in GlaxoSmithKline’s DMPK bioanalytical labs, and discuss current studies and evaluations looking at establishing best practice recommendations for the collection and freezing of pre-clinical and clinical samples, to ensure the best possible uniformity of analyte distribution for frozen aliquotting.
Speaker: Glenn Smith, Independent Scientific Consultant for CryoXtract, and Former Section Manager of the DMPK bioanalytical labs at GlaxoSmithKline Inc. in Research Triangle Park, NC
Automated Frozen Sample Aliquotting: Improving Bioanalytical Assay Results for Labile Molecules Sep 27, 2016

主题演讲:
- 李振亚 博士, CST中国及亚太区学术经理
- 裴华东 教授, 研究员、博士生导师 DNA损伤应答研究课题组组长, 中国国家蛋白科学研究中心
利用前沿蛋白质组技术,解读肿瘤发生关键信号通路及进行新分子靶标鉴定 Aug 31, 2016

LifeSciences - Histological phenotypes generally play an essential role in diagnostics, but in particular in oncology there is a growing need for selecting the right patients for the right treatments based on information derived from tissue slides
Speakers: Dr. Ralf Huss, Chief Medical Officer, Definiens AG
Alan Jerusalmi, PhD, Global Head of Professional Services, Definiens Inc.
Integrated Tissue Phenomics® and Big Data for Biomarker Discovery and Test Development Jul 19, 2016

LifeSciences - Immuno-oncology and transplantation medicine share the medical need for robust, immune cell-based biomarkers extracted from tissue biopsies. In an interdisciplinary approach, the Tissue Phenomics® methodology is applied to mine clinically annotated image data.
Speakers: Prof. Dr. med. Friedrich Feuerhake, Consultant in Neuropathology and Head of Digital Pathology Group, Hanover Medical School, Germany
Dr. Ralf Schönmeyer, Senior Research Scientist, Definiens AG
Tissue Phenomics® at Work for Immuno-Oncology and Transplantation Medicine Jun 27, 2016

LifeSciences - Join this webinar and consider the potential of collaborative partnerships between academicians, clinical investigators and contract research organizations in delivering new therapies for patients with diabetic nephropathy
Speakers: George L. Bakris , MD, Hon. DSc, F.A.S.H, F.A.S.N., F.A.H.A., Professor of Medicine, Director, ASH Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL
Michael D. Cressman, D.O., Senior Medical Director, Covance
Jennifer Ennis, MD, Medical Director, Litholink Corporation, A LabCorp Company
Applying Advanced Informatics to Accelerate Drug Development in Diabetic Nephropathy May 6, 2016

LifeSciences - The presentation includes a discussion of known or suspected mechanisms that mediate protection elicited by very different licensed vaccines: MMRV (anti-Measles, -Mumps, -Rubella and -Varicella), Pertussis (anti-whooping cough), and the recently introduced anti-serogroup B meningococcal vaccines
Speaker: Rolando Pajon, PhD , Vaccine Validation Scientist, Vaccine and Novel Immunotherapeutic Laboratory Solutions, Covance
Immunological Mechanisms of Vaccine-elicited Protection: Licensed Vaccines Apr 28, 2016

LifeSciences - Effective miRNA profiling calls for reproducible, sensitive and specific tools with turn-around times fast enough to support investigations into what can be a rapidly changing disease progression and treatment environment
Speaker: Simon Baker PhD, Global R&D Director, Bioline Reagents Ltd
MicroRNA Profiling Using a Rapid and Highly Sensitive qPCR Feb 18, 2016

LifeSciences - Dr. Murphy will discuss the findings from a recent evaluation made by Charles River Laboratories regarding the responsiveness of several syngeneic murine tumor models to antibody-based, immune checkpoint inhibitor therapeutics targeting CTLA-4 and PD-1, and detail the benefits of a multidisciplinary approach to cancer immunotherapy efficacy study design and execution
Speaker: Joseph Murphy, Ph.D., Director of R&D, Oncology, Charles River Laboratories
Cancer Immunotherapy: Advancing and Accelerating Discovery Programs Jan 25, 2016

LifeSciences - Roche NimbleGen has designed a panel to capture 6.5 Mb of DNA, targeting over 300 hdCNVs and non-exonic PGx content
Speakers: Dr. Brendan J. Keating, Assistant Professor of Pediatrics and Surgery, Perelman School of Medicine, University of Pennsylvania
Targeted Sequencing as a Tool to Understand the Genetic Basis of Transplant Rejection Nov 17, 2015

LifeSciences - Dr.Harder will present the Tissue Phenomics methodology to discover new tissue-based diagnostics using image and clinical data from prostate cancer patients with similar pathologies and known clinical outcome
Speaker: Nathalie Harder, PhD, Research Scientist, Definiens AG
How to Discover Powerful Tissue-Based Prognostic Biomarkers for the Benefit of Individual Patients Nov 11, 2015

LifeSciences - The speaker will discuss how simultaneous analysis of coding and noncoding RNAs using QIAGEN’s complete sample-to-insight workflow can reveal the mysteries in your samples
Speaker: Brian Dugan, MS, Global Product Manager, QIAGEN
Total RNA Discovery: Studying Gene Expression One Transcript at a Time Nov 11, 2015

LifeSciences - In order to generate reliable immune monitoring data that will help us determine the safety and efficacy of the therapeutic intervention approach from a global study, highly standardized methods to collect, process and prepare patient samples need to be implemented
Speaker: Sinnathamby Gomathinayagam, PhD, Senior Scientist, Translational Biomarkers Solutions, Covance
Recent Advances in Immune Monitoring Nov 5, 2015

LifeSciences - This webinar summarizes key aspects of evaluating safety and efficacy in studies of immune checkpoint inhibitors and describes operational strategies that support successful trial execution and regulatory approval
Speakers: Thomas Moehler, MD, PhD, Vice President, Medical & Scientific Affairs, Hematology/Oncology, inVentiv Health
Cheryl Askew, PhD, Senior Director, Program Delivery, Hematology/Oncology, inVentiv Health
Jessica Lee, PhD, Senior Engagement Manager, Campbell Alliance (an inVentiv Health Company
Immuno-Oncology Clinical Trials: Best Practices for Clinical Development of Immunotherapies Nov 4, 2015

LifeSciences - Topics include "Deciphering the Molecular Pathology of Alzheimer’s Disease" and " The Use of Highly Validated Antibodies to Study Neurodegenerative Disease"
Speakers: Li-Huei Tsai, Ph. D, Picower Professor of Neuroscience, The Picower Institute for Learning and Memory, Broad Institute, Senior Associate Member, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology
Raphael Rozenfeld, Ph.D, Development Scientist, Cell Signaling Technology
Immunolabeling for Neurodegenerative Diseases Oct 28, 2015

LifeSciences - The speakers will discuss a menu of genomic tests developed to supplement many endpoints for complex clinical trials, including a Comprehensive Cancer Panel (Q2 Solutions CCP), HLA typing, exome sequencing and pan-cancer immune-profiling, to set the stage for more precise and individualized therapeutics, also known as precision medicine
Speakers: Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions, a Quintiles Quest Joint Venture
Victor Weigman, Ph.D., Associate Director, Translational Genomics, Q2 Solutions, a Quintiles Quest Joint Venture
Precision Medicine: Shifting from One Drug for All Trials to Targeted Therapy Trials Oct 28, 2015

LifeSciences - The speakers  will revisit the central dogma of molecular biology with respect to single-cell DNA-RNA co-analysis, and cell heterogeneity.
Speakers: Rong Fan, Ph.D., Associate Professor of Biomedical Engineering, Yale University
Ioanna Andreou, Ph.D., Senior Scientist, QIAGEN
Revisiting the Central Dogma of Molecular Biology at the Genome Scale and in Single Cells Oct 20, 2015

LifeSciences - Quanterix and Myriad RBM are working together to use ultrasensitive, high quality immunoassay services that offer drug developers an unparalleled approach to clinical research
Speakers: Mark Roskey, Ph.D., VP/GM, Applications and Reagents, Quanterix
Dominic Eisinger, Ph.D., Vice President of Sales and Marketing, Myriad RBM
Detecting the Undetectable: Development & Validation of Ultrasensitive Simoa-based Immunoassay Services Oct 20, 2015

LifeSciences - This webinar will focus on the analytical validation of in-vitro diagnostic devices, the process through which one gains assurance that the data delivered by in-vitro diagnostic devices are ‘reliably correct’, the prerequisite for in-vitro diagnostic devices' clinical use
Speakers: Elisabeth (Els) Coart, PhD, Senior Research Biostatistician, IDDI
Hugo Vanderstichele, PhD, Co-Founder and Director Assay Development, ADx NeuroSciences
From Biomarker to In-Vitro (Companion) Diagnostic Device:
How to Design and Conduct Efficient Analytical Validation Studies in Accordance with CLSI Guidelines
Oct 19, 2015

LifeSciences - With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed assays for both research and clinical purposes
Speaker: Matthew R. Silver, Ph.D, Principal Scientist, Translational Assays, Cell Signaling Technology
Analysis of Immune Checkpoint Control Protein Co-expression in Breast and Ovarian Cancer Using Novel Rabbit Monoclonal Antibodies and Multiplex IHC Oct 7, 2015

LifeSciences - The speaker  will discuss exosome composition, different sources of RNA in biofluids, isolation approcahes and clinical applications of exosome biomarkers.
Speaker: Dr. Johan Skog, Chief Scientific Officer and Founding Scientist, Exosome Diagnostics
Exosome RNA for Biomarker Development Oct 6, 2015

LifeSciences - This webinar will show how Tissue Phenomics® can be utilized to identify previously undiscovered prognostic and predictive image-based features or combinations of features for patient stratification
Speaker: Peter Caie, PhD, Senior Research Fellow in Quantitative and Systems Pathology, University of St Andrews
Applying Tissue Phenomics® to Clinical Questions for Patient Stratification Sept 23, 2015

 

LifeSciences - In this case study, the speakers will show the power of using a novel combination of machine learning algorithms with a systems biology based approach for identifying genes and the subsequent exonic regions driving prognosis for patients with lung squamous cell carcinoma (SQCC)
Speakers: Scott Marshall, Ph.D., Managing Director, Analytics, Precision for Medicine
Jared Kohler, Ph.D., Managing Director, Analytics, Precision for Medicine
Tobias Guennel, Ph.D., Principal, Analytics, Precision for Medicine
Applying Systems Biology and Predictive Genomic Analytics on Patients with Lung Squamous Cell Carcinoma and RNA-Seq Gene Expression Sept 14, 2015


LifeSciences - Quanterix and Myriad RBM are working together to use ultrasensitive, high quality immunoassay services that offer drug developers an unparalleled approach to clinical research
Speakers: James P. Mapes, Ph.D., Chief Scientific Officer, Myriad RBM
Mark Roskey, VP/GM, Applications and Reagents, Quanterix
Detecting the Undetectable: Development & Validation of Ultrasensitive Simoa-based Immunoassay Services Aug 25, 2015
LifeSciences - The identification and quantification of post-translationally modified peptides will be discussed, as well as multiplexed quantitative ubiquitylome analysis utilizing ubiquitin remnant immunoprecipitation, nLC-MS/MS, andiIsobaric labels
Speakers: Matthew P. Stokes, PhD, Principal Scientist, Proteomics Group, Cell Signaling Technology, Inc.
Christopher Michael Rose, Postdoctoral Research Fellow, Gygi Lab Harvard Medical School
Post Translational Modification: Antibody Enrichment for Mass Spectrometry Based Proteomics Jul 15, 2015

LifeSciences - In this webinar, the successful development and commercialization of companion diagnostics (CDx) will be discussed by experts from Covance and LabCorp.
Speakers: Mark Roberts, Ph.D., Director of Diagnostics Development, Covance
Alan Wookey, Associate Vice President and Executive Director of Companion Diagnostics, Covance
Pathway Considerations to CDx Development and Commercialization Jun 30, 2015

 

LifeSciences - The presenters will discuss new solutions and strategies for streamlined glycosylation analysis
Speakers: Alicia Bielik, PhD, Product Manager, Glycobiology, New England Biolabs
Paula Magnelli, PhD, Scientist, Glycobiology, New England Biolabs
Improved Methods for Structural Characterization of Therapeutic Proteins Jun 19, 2015
LifeSciences - This webinar will discuss the rationale for including functional assessments in repeat-dose toxicology studies, how the data can be used for more impactful risk assessments, and the potential for more relevant clinical biomarker strategies
Speakers: Brian R. Berridge, DVM, PhD, DACVP, Director and Head of WW Animal Research Strategy in the Office of Animal Welfare, Ethics and Strategy, GlaxoSmithKline
Jonathan Heyen, M.S., D.A.B.T., Senior Principal Scientist - Safety Pharmacology Department, Pfizer La Jolla
Structural and Functional Endpoints in Repeat-Dose Toxicity Cardiovascular Risk Assessments and the Use of In Vivo Physiologic Monitoring May 20, 2015
LifeSciences - This webinar will go into detail on how to devise a method of quantitative IHC assay design that overcomes the inherent challenges of traditional IHC assays
Speaker: Sharon Moulis, PhD, Director, Tissue Diagnostics Alliances, Definiens
How to Develop Fit-for-Purpose Quantitative IHC Assays to Enable Clinical Trial Patient Stratification May 13, 2015
LifeSciences - This webinar will review strategies for accessing the expression profiles of mRNA, lncRNA, and miRNA in both solid tissues and liquid biopsies, and describe the application of human micronome profiling in liquid biopsies to the development of an early minimally invasive biomarker for detection of early stage acetaminophen poisoning in patients
Speakers: Eric Lader, Senior Director of Product Development, QIAGEN
James Dear, Senior Clinical Lecturer in Clinical Pharmacology, Royal Infirmary of Edinburgh/Edinburgh University
RNA Biomarker Development: From Sample to Insight May 13, 2015
This webinar is intended to help Oncology drug developers explore Biomarkers in the design of clinical trials
Speakers: Kamala Maddali, DVM, PhD, Director of Scientific Development, Quest Diagnostics Clinical Trials
Arturo Anguiano, MD, FFACMG, International Medical Director – Medical Affairs, Quest Diagnostics
Frederick K. Racke, M.D.,Ph.D., Medical Director, Hematopathology and Coagulation, Quest Diagnostics Nichols Institute
Emerging Role of Biomarkers in Improving the Success Rate of Early Oncology Drug Development Mar 31, 2015
The talk will highlight the reasons for the development of the service and give some details on the potential benefits to biopharma. Almac have developed a service to enable biomarker studies to be carried out retrospectively in trials where there was not one in place from the start.
Speakers: Dr. Peter Kerr, Head of Project Management & Product Development, Almac Diagnostics
Kinga Wojciechowska, Project Manager - Ethics/Tissue Collection, Almac Diagnostics
Retrospective Sample Collection
Sample Access and Profiling for Biomarker Discovery to Help Rescue or Reposition your Drug
Mar 25, 2015
Recent Standardization and harmonization of methodologies across multicenter allergy and respiratory trials with induced sputum biomarkers as a primary outcome
Speakers: Graham Clarke, PhD, Senior Director and Head of Respiratory & Inflammation, Quintiles Early Clinical Development
Neil Alexis, PhD, Professor, Department of Pediatrics, Division of Allergy Immunology Rheumatology and Infectious Disease, University of North Carolina at Chapel Hill
Improving the Quality of Allergy and Respiratory Clinical Research Using Induced Sputum Biomarkers Dec 2/14
Learn about the details of the candidate identification, assay development, testing and results, beginning with the derivation of the initial list of candidates, to the identification of the five blood-based proteins, which together constitute the biomarker panel used in the commercial protein expression test, developed by Caprion Proteomics in collaboration with Integrated Diagnostics (InDi)
Speaker: Daniel Chelsky, Chief Scientific Officer, Caprion Proteomics
A Blood-Based Proteomic Classifier for the Molecular Characterization of Pulmonary Nodules:
A Case Study in the Discovery and Validation of a Molecular Diagnostic Using Caprion’s Technology Platform
Dec 9/13
In this webinar, Dr. Eisinger will describe the development and validation of a multiplex panel of biomarkers for quantifying the commitment, onset, and induction of apoptosis by the intrinsic pathway in tumor tissue samples
Speaker: Dominic Eisinger, PhD, Director of Strategic Development, Myriad RBM
Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue using Myriad RBM’s Multiplex ApoptosisMAP™ Nov 22/13
This presentation will discuss how the LCMS Biomarkers and Biologics Services business at Quintiles has partnered with a sponsor to develop methods that compare the surrogate matrix and surrogate analyte approaches for the analysis of five amino acids in human plasma: alanine, valine, methionine, leucine and isoleucine
Speaker: Barry R. Jones, Ph.D., Assistant Research Investigator, LCMS Biomarkers and Biologics, Quintiles Bioanalytical and ADME Labs
Better Methods for Novel Biomarkers Series:
LC/MS Biomarker Assay Validation Strategies Using Surrogate Matrix and Surrogate Analyte Approaches
Oct 3/13
This webinar and panel discussion focuses on new ways to design biomarker driven trials and access the right patients, as well as demonstrate the power of the Total Cancer Care data warehouse, featuring participation from Millennium Pharmaceuticals
Speakers: Kyle Kuvalanka, MBA, VP, Strategy and Business Development, Millennium Pharmaceuticals
William (Bill) Trepicchio, PhD, Senior Director, Translational Medicine, Millennium Pharmaceuticals
William Dalton, PhD, MD, CEO, M2Gen and Director, Personalized Medicine Institute at Moffitt Cancer Center
Frank Makosiej, PharmD, Executive Director, Operations, Strategy and Planning, Covance
Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials Sep 12/13
A discussion of platforms, platform selection and migration, optimising tests for FFPE tissue, clinical delivery for trial enrichment, and development routes for companion diagnostics
Speaker: Dr. Austin Tanney, Scientific Liaison Manager, Almac
Optimizing Assays from FFPE for Biomarker Strategies Sep 4/13
This presentation will discuss how the LCMS Biomarkers and Biologics Services business at Quintiles has partnered with our sponsors to develop quantitative methods for biomarkers and biotherapeutics by adapting the immunoprecipitation methodologies of ELISA with the specificity and robustness of LCMS to achieve sensitivity that is comparable to ELISA but with the specificity of LCMS
Speaker: Gary Schultz Ph.D., Director, LCMS Biomarkers and Biologics, Quintiles Bioanalytical and ADME Labs
Quantitative Analysis of Biomarkers with the Specificity and Robustness of Liquid Chromatography/Mass Spectrometry (LC/MS) and the Sensitivity of ELISA Jun 27/13
This webinar will discuss the benefits of partnering with an academic medical center and will feature case studies for successful biomarker discovery, biomarker development and companion diagnostics co-development
Speakers: Steve Groshong, MD, PhD, Pathology Division Chief, National Jewish Health
Preveen Ramamoorthy, PhD, Molecular Diagnostics Laboratory Director, National Jewish Health
Leveraging an Academic-Industry Partnership for Commercial Success Jun 13/13
LifeSciences This webinar focuses on OncoPanelTM,, a collection of 240 genomically and histologically diverse cancer cell lines, that providesmultiplexed high-content imaging analysis of therapeutics in oncology
Speakers: O. Jameel Shah, Ph.D, Principal Scientist and Group Leader, Oncology, Eurofins Panlabs
Jonathan Crane, Ph.D., Senior Scientist, Oncology and Cell Biology, Eurofins Panlabs
Predictive Biomarker Discovery for Oncology Small-Molecules and Biologics May 22/13
LifeSciences Learn how Caprion applies its label-free mass spectrometry-based proteomics platform to successfully identify tissue-specific protein biomarkers that can be used to follow disease progression in human blood
Speaker: Eustache Paramithiotis, Ph.D., Senior Director, Molecular and Cell Biology, Caprion
Discovery of Circulating Protein Biomarkers by Analysis of the Tissue Secretome May 21/13
LifeSciences This webinar is part of a series about innovative approaches and specialized techniques to bioanalytical studies
Speaker: Clark Williard, Executive Director, Mass Spectrometry Operations, PharmaNet/i3
Application of GC/MS/MS in Monitoring Steriods as a Pharmacokinetic and Pharmacological Biomarker Dec 17/12
LifeSciences This webinar presents an overview of some of the key components involved in developing products related to the application of biomarkers earlier in the drug development pipeline
Speakers: Tim Davison , B. Math, Ph.D., VP, Bioinformatics and Biostatistics, Almac Diagnostics
Susan Farragher, Operations Manager, Almac Diagnostics
Developing and Applying Biomarkers in Early Phase Clinical Trials

Oct 18/12

LifeSciences The webinar will examine operational and analytical considerations for early detection of potential organ toxicity
Speakers from ACM Global Central Laboratory:
Mark Engelhart, Chief Commercial Officer
Andrew Botham, PhD, Research & Development Manager
Maria-Magdalena Patru, MD, PhD, Scientific Affairs Medical Liaison
Drug-Induced Organ Toxicity (DIOT): The Early Detection and Management of Elevated Biomarkers to Ensure Patient Safety Oct 17/12
LifeSciences Learn about a new transformative proteomic biomarker discovery technology that measures over 1129 human proteins in small sample volumes with a sensitive, specific and semi-automated assay
Speakers: Steve Williams, M.D., Chief Medical Officer, SomaLogic
Nick Saccomano, Ph.D., Chief Technology Officer, SomaLogic
Unlocking Protein Biomarker Discovery for Pharma, Biotech and Academia Aug 23/12
LifeSciences This webinar will review models available for assessing anti-inflammatory activity in vivo then focus on imaging technologies, for discovery screening and for translatable biomarkers as applied in inflammation models
Speakers: James Mobley, Ph.D., Founder and CSO, Sunapten Therapeutics, Inc.
Patrick McConville, Ph.D., COO, CSO and Co-founder, Molecular Imaging Inc.
Advances in Inflammation Models and Associated Drug Evaluation: Improved Assessment Using Imaging Biomarkers Jun 26/12
LifeSciences Learn how Caprion accelerates validation of biomarkers, diagnostics, and toxicology profiles using MRM technology. A variety of sample types and applications will be covered, including plasma proteins, immune response, toxicology, and tissue-specific panels
Speaker: Daniel Chelsky, Chief Scientific Officer, Caprion Proteomics
New Solutions for Highly Multiplexed Protein Assays via MRM Jun 4/12
LifeSciences This presentation will include a brief background on the development & validation of Vectra DA delivered by Dr. David Chernoff, followed by a patient case study discussion led by Dr. Alvin Wells highlighting the application of Vectra DA in clinical practice
Speakers: Alvin Wells, MD, PhD, Director, Rheumatology and Immunotherapy Center
David Chernoff, MD, Chief Medical Officer, Crescendo Bioscience®, Inc.
Clinical Applications of Vectra™ DA, a Multi-Biomarker Blood Test for Rheumatoid Arthritis Disease Activity May 15/12
LifeSciences An examination of the complex process of translating biomarkers into clinically applicable tests and their use in clinical trials
Speakers: Dr. Peter Kerr, Product Development Team Manager, Almac
Dr. Stephen Moore, Product Development Team Manager, Almac
Translating Pre-clinical Markers to Validated Assays and Their Application to Clinical Trials for the Pharma Industry Jan 19/12
LifeSciences Topics include evaluating CTCs as prognostic and predictive tools, obtaining extensive biomarker data without invasive procedures, and personalized therapy based upon CTC molecular pathology
Speaker: Ken Pennline, PhD, Vice President and Global Head, Cytometry Services, Esoterix Clinical Trials Services, a Division of LabCorp
Circulating Tumor Cells as a Biomarker Approach in Oncology Nov 9/11
LifeSciences Join this webinar and learn how some of the major challenges of biomarker discovery can be addressed in an integrated manner, how to discover and select the biomarker models most suitable for independent validation, and the importance of functional analysis as an essential component of biomarker discovery
Speakers: Max Bylesjo, Ph.D., Bioinformatics Team Leader, Almac
Nicolas Goffard, Ph.D, Bioinformatics Scientist, Almac
An Integrated Approach to Biomarker Discovery Mar 28/11

Click here for a list of upcoming Web Conferences

 
Copyright © 2016-2017 Honeycomb Worldwide Inc.